Gilead (GILD) executive says Anito-Cel could address an up to USD 20bln multiple myeloma opportunity when considering use in first-line treatment, via TD Conference
Importance
Level 1
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#GILEAD SCIENCES INC#GILD.US#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#GILD#DXY#US EQUITIES